Life-Saving Dividends for Synthetic Biology Research: Microbial-Based Antimalarial Drug Shipped to Africa

August 13, 2014

A project begun some 13 years ago by Jay Keasling, CEO of the Joint BioEnergy Institute (JBEI), has culminated in the shipment of 1.7 million treatments of semi-synthetic artemisinin to malaria-endemic countries in Africa.

Read more